Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions

Journal of Surgical Oncology

Volumn 62, Issue 2, 1996, Pages 135-138

  Kurihara, Naoto ^a   Kubota, Tetsuro ^a   Hoshiya, Yasunori ^a   Otani, Yoshihide ^a   Ando, Nobutoshi ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

area under the curve (AUC); cis diamminedichloroplatinum(II); holding time; low dose consecutive infusion; pharmacokinetics

Indexed keywords

CISPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG INFUSION; ESOPHAGUS CANCER; GASTROINTESTINAL SYMPTOM; HUMAN; HYDRATION; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; ESOPHAGEAL NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 0029948891     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199606)62:2<135::AID-JSO10>3.0.CO;2-7     Document Type: Article

References (27)

1. Watanabe S, Tsugane S, Ohno Y: Prediction of the gastric cancer mortality in 2000 in Japan. Jpn J Cancer Res 79:439-444, 1988.
2. Nippon Kayaku, Co. Ltd.: Package insert of Landa(R), 1994.
3. Beer M, Cocconi G, Ceci G, et al.: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19:712-720, 1983.
4. Lacave AJ, Pereda MV, Izarzugaza I, et al.: Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 6:35-38, 1983.
5. Leichman L, McDonald B, Dindogru A, et al.: Cisplatin: An active drug in the treatment of disseminated gastric cancer. Cancer 53:18-22, 1984.
6. Aabo K, Pedersen H, Rorth M: Cisplatin in the treatment of advanced gastric carcinoma: A phase II study. Cancer Treat Rep 69:449-450, 1985.
7. Perry MC, Green MR, Mick R, Schein P: Cisplatin in patients with gastric cancer: A cancer and leukemia group B phase II study. Cancer Treat Rep 70:415-416, 1986.
8. Ishibiki K, Kumai K, Kodaira K, et al.: Phase II study with cisplatin in advanced stomach and colon carcinoma. Jpn J Cancer Chemother 16:3185-3193, 1989 [in Japanese, with English abstract].
9. Miyamoto K, Yoshida S, Saito D, et al.: Pilot phase II study of cis-diamminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol 20:169-176, 1990.
10. Comis RI, Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1:221-238, 1974.
11. Loehrer PJ, Einhorn LH: Cisplatin. Ann Intern Med 100:704-713, 1984.
12. Chen JT, Hirai Y, Nakayama K, et al.: CDDP-ACR treatment for patients with recurrent ovarian cancer with prior chemotherapy containing CDDP. Acta Obst Gynecol Jpn 41:1565-1570, 1989.
13. Forastiere AA, Belliveau JF, Goren MP, et al.: Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer. Cancer Res 48:3869-3874, 1988.
14. Jacobs C, Bertino JR, Goffinet DR, et al.: 24-hour infusion of cisplatin in head and neck cancer. Cancer 42:2135-2140, 1978.
15. Kurihara N, Kubota T, Hoshiya Y, et al.: Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro. J Surg Oncol. 60:238-241, 1995.
16. Kurihara N, Kubota T, Hoshiya Y, et al.: Antitumor activity of cis-dichlorodiammineplatinum(II) against human tumor xenografts in nude mice depends on its area under the curve. J Surg Oncol 61:138-142, 1996.
17. Kurihara N, Kubota T, Hoshiya Y, et al.: Antitumor activity of cisplatin administered as a consecutive infusion in vivo against human gastric cancer in nude mice. J Jpn Assoc Cancer Ther 30:1729-1734, 1995 [in Japanese, with English abstract].
18. LeRoy AF, Wehling ML, Sponseller HL, et al.: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184-191, 1977.
19. Kubota T, Inoue S, Furukawa T, et al.: Similarity of serum-tumor pharmacokinetics of antitumor agents in man and nude mice. Anticancer Res 13:1481-1484, 1993.
20. Forastiere AA, Takasugi BJ, Baker SR, et al.: High dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19:155-158, 1987.
21. Chary KK, Kighby DJ, Henderson ES: A phase II study of high dose cis-diamminedichloroplatinum II with forced diuresis. J Clin Hematol Oncol 7:633-644, 1977.
22. Takahashi K, Ebihara K, Honda Y, et al.: Antitumor activity of cis-dichlorodiammineplatinum (II) and its effect on cell cycle progression. Jpn J Cancer Chemother 9:624-631, 1982 (in Japanese, with English abstract].
23. Shimoyama M: Implication of cell-kill kinetics of anticancer agents in the design of optimal therapeutic schedules. Jpn J Cancer Chemother 3:1103-1110, 1976 [in Japanese].
24. Van Harskamp G, Boven E, Vermerken JB, et al.: Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC). Int J Radiation Oncology Biol Phys 13:1735-1738, 1987.
25. Yong SC, Yamashita Y, Nakata B, et al.: Combination therapy of 5-FU and low dose CDDP for advanced and recurrent gastric cancer. Jpn J Cancer Chemother 22:149-151, 1995 [in Japanese, with English abstract].
26. Belliveau JF, Posner MR, Ferrari L, et al.: Cisplatin administered as a continuous 5-day infusion: Plasma platinum levels and urine platinum excretion. Cancer Treat Rep 70:1215-1217, 1986.
27. Holdener EE, Pari CH, Belt RJ, et al.: Effect of mannitol and human plasma and cytotoxicity of cis dichlorodiammineplatinum. Clin Res 26:436A, 1978.